Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Navidea Biopharma (NAVB) Reports Q4 Loss of $0.02
March 7, 2019 4:28 PM ESTNavidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.02), versus ($0.04) reported last year. Revenue for the quarter came in at $119.32 thousand, versus $391.49 thousand reported last year.
Navidea had a productive quarter as we advanced the business and our novel imaging pipeline, said Mr. Jed A.... More
